Results 261 to 270 of about 262,962 (308)

Induction Chemotherapy: To Use or Not to Use? That Is the Question

Seminars in Radiation Oncology, 2009
The intensification of radiation, induction chemotherapy, and concomitant chemoradiotherapy has been extensively investigated over the past 2 decades for the nonsurgical management of locally advanced, nonmetastatic squamous cell head and neck cancer (HNC).
David M, Brizel, Everett E, Vokes
openaire   +2 more sources

Intra-arterial induction chemotherapy

Oncology Reports, 1996
When effective anti-cancer drugs first became available to clinicians they were commonly used by surgeons by intra-arterial infusion to treat difficult regional cancer problems. Because they were most often used to treat poorly vascularised recurrent cancers results were, in general, unsatisfactory.
openaire   +2 more sources

INDUCTION CHEMOTHERAPY IN HEAD AND NECK CANCER

Hematology/Oncology Clinics of North America, 1999
Induction chemotherapy can produce response rates of 60% to 90%, which are complete in 20% to 50% of previously untreated patients with squamous cell head and neck cancer. It was hoped that this dramatic chemotherapy-induced tumor shrinkage would result in more successful locoregional treatment and prove useful in disease management.
openaire   +2 more sources

Organ Preservation-Induction Chemotherapy

2006
Induction chemotherapy consisting of high dose cisplatin and infusional 5-FU (PF) followed by definitive radiation therapy for the past decade has been the organ-sparing alternative to surgery for patients with laryngeal and hypopharyngeal squamous cell carcinomas.
openaire   +2 more sources

[Rationalization of adjuvant chemotherapy by induction chemotherapy].

Bulletin du cancer, 1985
An induction chemotherapy, before any local treatment, allows to precise the chemosensitivity of the primary tumor. These data may help to improve indication and type of a further adjuvant chemotherapy. However there are many biological differences between different sites of the same tumor and along the time, without or after treatment.
B, Hoerni, J, Chauvergne
openaire   +1 more source

Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma

Cancer, 2020
NPC‐0501 has shown that induction chemotherapy provides a survival benefit for patients with locoregionally advanced nasopharyngeal carcinoma and has added evidence to current knowledge. In the intensity‐modulated radiotherapy era, neoadjuvant chemotherapy should be considered at least for patients with high‐risk disease.
Stefano Cavalieri, Lisa Licitra
openaire   +2 more sources

Induction chemotherapy in head and neck cancer

Anti-Cancer Drugs, 2011
Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a high cure rate while preserving ...
Pointreau, Yoann, Atean, Ibrahim, Fayette, Jérome, Calais, Gilles, Lefebvre, Jean Louis   +4 more
openaire   +3 more sources

Induction chemotherapy using intraarterial infusion

1991
Until recently gastrectomy was the only treatment offering any real prospect of cure for patients with gastric cancer. However, excepting patients with minimal disease, the results of gastrectomy alone have been unsatisfactory, whether the gastrectomy has been total or subtotal.
openaire   +2 more sources

Induction Chemotherapy for Hepatocellular Carcinoma

2011
Hepatocellular carcinoma (HCC) is known as a relatively chemoresistant tumor, and systemic cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Other systemic therapies including hormonal therapy and immunotherapy have also been disappointing.
Takumi Fukumoto, Yonson Ku
openaire   +1 more source

Induction of diffuse necrotizing enterocolitis by anticancer chemotherapy

Gastroenterologia Japonica, 1987
Fulminant, necrotizing colitis is a frequent, and generally fatal, complication of severe granulocytopenia, occurring during the treatment of hematological malignancies. In these cases, the patient complains of severe peritonitis, including nausea, vomiting, abdominal pain, diarrhea or melena, and a high temperature.
M, Maeta, K, Mizusawa, S, Koga
openaire   +2 more sources